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A B S T R A C T
Background: The presence of pharmaceuticals in the environment is a growing global concern and although
environmental risk assessment is required for approval of new drugs in Europe and the USA, the adequacy of the
current triggers and the eﬀects-based assessments has been questioned.
Objective: To provide a comprehensive analysis of all regulatory compliant aquatic ecotoxicity data and evaluate
the current triggers and eﬀects-based environmental assessments to facilitate the development of more eﬃcient
approaches for pharmaceuticals toxicity testing.
Methods: Publicly-available regulatory compliant ecotoxicity data for drugs targeting human proteins was
compiled together with pharmacological information including drug targets, Cmax and lipophilicity. Possible
links between these factors and the ecotoxicity data for eﬀects on, growth, mortality and/or reproduction, were
evaluated. The environmental risks were then assessed based on a combined analysis of drug toxicity and
predicted environmental concentrations based on European patient consumption data.
Results: For most (88%) of the of 975 approved small molecule drugs targeting human proteins a complete set of
regulatory compliant ecotoxicity data in the public domain was lacking, highlighting the need for both in-
telligent approaches to prioritize legacy human drugs for a tailored environmental risk assessment and a
transparent database that captures environmental data. We show that presence/absence of drug-target ortho-
logues are predictive of susceptible species for the more potent drugs. Drugs that target the endocrine system
represent the highest potency and greatest risk. However, for most drugs (> 80%) with a full set of ecotoxicity
data, risk quotients assuming worst-case exposure assessments were below one in all European countries in-
dicating low environmental risks for the endpoints assessed.
Conclusion: We believe that the presented analysis can guide improvements to current testing procedures, and
provide valuable approaches for prioritising legacy drugs (i.e. those registered before 2006) for further eco-
toxicity testing. For drugs where eﬀects of possible concern (e.g. behaviour) are not captured in regulatory tests,
additional mechanistic testing may be required to provide the highest conﬁdence for avoiding environmental
impacts.
1. Introduction
Pharmaceuticals are present in the environment as a consequence of
patient use, drug production and formulation, and improper disposal
(Boxall et al., 2012). They predominantly enter the aquatic environ-
ment and are typically found in concentrations from sub-ng/l to a few
μg/l (Weber et al., 2015). Extremely high pharmaceutical
concentrations, in the order of mg/l, however, have been detected in
some industrial eﬄuents and recipient streams, for example in India,
China, USA, Korea and Israel (Larsson, 2014). Drugs are also found in
the terrestrial environment through the application of sewage sludge to
land, leaching from landﬁlls, or irrigation of arable land with treated or
untreated wastewaters (Kümmerer, 2008). There is precedence for ad-
verse eﬀects of drugs in wildlife. In particular, the non-steroidal anti-
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inﬂammatory drug diclofenac has been shown to cause dramatic po-
pulation declines (> 99%) in Gyps vulture species in India and Paki-
stan, resulting in localised extinctions (Oaks et al., 2004). The vultures
suﬀered from renal failure after feeding on dead cattle that had been
treated with diclofenac. The contraceptive, ethinylestradiol (EE2), to-
gether with a range of other natural and synthetic estrogens, has been
shown to cause feminisation in male ﬁsh in rivers (Desbrow et al., 1998;
Jobling et al., 1998; Lange et al., 2009). The purpose of conducting
regulatory environmental risk assessments is to avoid similar ecological
situations in the future; to protect the most vulnerable wildlife popu-
lations, ecosystem services and, by association, the wider human po-
pulation.
In the European Union (EU) and the United States (US) an en-
vironmental risk assessment is required for approval of new drugs, and
this is usually conducted alongside Phase III clinicals just prior to
submission of the marketing application. Chronic ecotoxicity testing
has however only been required since 2006 in the EU and is not ne-
cessarily required in the US (European Medicines Agency, 2006; Food
and Drug Administration, 1998). Most of the legacy drugs (i.e. those
registered before 2006) are therefore lacking chronic ecotoxicity data
but the extent of the issue is not known as most regulatory compliant
data are not accessible.
In the EU aquatic eﬀects studies are triggered if the Predicted
Environmental Concentration (PEC) exceeds 0.01 μg/l (European
Medicines Agency, 2006) and in the US if the Expected Environmental
Concentration exceeds 0.1 μg/l (Food and Drug Administration
Guidance for industry, 1998). Eﬀects studies are also required if the
drug is highly lipophilic (logD≥ 4.5) and potential endocrine dis-
ruptors aﬀecting reproduction trigger a tailored assessment in both the
EU and US, independent of any exposure information (European
Medicines Agency, 2006, 2010; Food and Drug Administration 1998;
2016). The ecological protection goal is directed at population, biodi-
versity and ecosystem services levels. In the case of threatened and
endangered species, the individual level of biological organisation is the
protection goal but this is not considered in the current testing ap-
proach for chemicals and as such is a recognised limitation. Endpoints
in the required toxicity testing are growth, mortality and reproduction.
Potential eﬀects on molecular, cell, or tissue level responses or on de-
velopmental or behavioural eﬀects are typically not considered. There
is growing concern and debate regarding the need to include for ex-
ample behavioural eﬀects, especially for psychoactive drugs, and other
non-standard endpoints such tissue level damage (e.g. as assessed via
histopathology). Better understanding of how tissue, developmental
and behavioural level eﬀects may be extrapolated to possible impact on
wild populations and ecosystem services, is however needed to de-
termine their signiﬁcance. Equally, however, this also applies to all
other chemicals tested in regulatory risk assessment frameworks and
this debate is beyond the scope of the analyses conducted here for
pharmaceuticals.
The adequacy of the current regulatory test triggers and the eﬀects-
based assessments are also questioned because they rely on tests de-
veloped to determine the acute toxicity of industrial chemicals and do
not consider the considerable safety and pharmacology information
that is available for pharmaceuticals (Ågerstrand et al., 2015; European
Medicines Agency, 2016). During the development of a new medical
product, safety assessments of the active drug ingredient and the pro-
duct are performed to show that the medicine is eﬀective and that its
beneﬁts outweigh any potential adverse side-eﬀects. It is therefore
perhaps unlikely that drugs would be highly toxic to wildlife unless
therapy-related eﬀects lead to toxicity. The potential use of preclinical
and clinical data to improve the environmental risk assessment has
been suggested previously based on theoretical reasoning and applied
to data for a few case studies only (Gunnarsson et al., 2012; Winter
et al., 2010). Furthermore, the suggested approaches have not been
validated against a comprehensive dataset of comparable chronic
endpoints across a wide range of drugs and species.
In the environmental risk assessment required for approval in the
EU, a Predicted No Eﬀect Concentration (PNEC) is established by the
application of an assessment factor of 10 to the lowest No Observed
Eﬀect Concentration (NOEC) for the endpoints of growth, development
and/or reproduction from species representing three trophic levels
(European Medicines Agency, 2006) and the PNEC is compared to a
predicted environmental concentration (PEC). The PEC is usually cal-
culated assuming the maximum dose is taken daily and that 1% of the
population takes that drug (unless robust epidemiology data exist
showing otherwise). The PEC also assumes 100% patient use, no wa-
stage, no patient metabolism or sewage treatment removal, 200 l of
wastewater per person per day and a dilution factor of 10 in the aquatic
environment. A risk quotient (PEC/PNEC) above 1 in the EU (or below
a safety margin of 10–1000, depending on the assessment tier in the
USA) triggers further evaluations and risk reﬁnement, for example on
the use, fate and behaviour of the drug. When the possibility for en-
vironmental risks cannot be excluded an evaluation of precautionary
and safety measures such as proposals for additional labelling of
package leaﬂets should be presented. Under current regulatory frame-
works, human drugs are approved for patient use irrespective of their
potential environmental hazard and risk. This is a unique regulatory
position for any class of chemical where the beneﬁt to society, here as
medicine, is automatically assumed to outweigh potential environ-
mental eﬀect; it is also an exception that is subject to greater scrutiny
and is currently under challenge (Ågerstrand et al., 2015; BIO
Intelligence Service, 2013).
We have compiled all publicly available regulatory compliant eco-
toxicity data-set for human drugs, based on the results reported in
regulatory submissions or presented voluntarily by the pharmaceutical
industry. The aim was to create a transparent database that captures the
regulatory compliant ecotoxicity data and to facilitate the development
of more eﬃcient approaches for prioritisation of environmental testing
eﬀorts for human drugs, whether new molecular entities or legacy
drugs. The majority of drugs are developed to speciﬁcally aﬀect human
proteins and we have focused our analysis on these drugs. Anti-in-
fectives and anti-parasitic drugs were excluded as a diﬀerent approach
for their evaluation would be needed and assessments of anti-infectives
are covered elsewhere (Brandt et al., 2015; Le Page et al., 2017).
We analysed possible links between taxa-speciﬁc environmental
toxicity, as measured by eﬀects on growth, mortality or reproduction,
and the evolutionary conservation of drug targets and looked to identify
patterns of environmental toxicity across diﬀerent therapeutic mode of
actions. Furthermore, potential links to lipophilicity were assessed and
we evaluated a previously suggested pharmacological-based approach
for prioritisation of drugs with increased risk of aﬀecting growth,
mortality or reproduction in ﬁsh. Finally, we estimated the environ-
mental risks of the drugs by a combined analysis of drug toxicity and
predictions of environmental concentrations based on European patient
consumption data. The results presented provide a comprehensive as-
sessment of what is known from the limited number of drugs and
therapeutic mode of actions with regulatory compliant environmental
eﬀect data. The analysis highlights some classes of therapeutic mode of
actions that are more likely to aﬀect growth, lethality or reproduction
and identiﬁes the susceptible trophic levels. Drugs and therapeutic
classes lacking ecotoxicity data are identiﬁed and the analysis provides
a data-driven basis for improved approaches for prioritising legacy
drugs (i.e. those registered before 2006) for further ecotoxicity testing.
2. Methods
2.1. The ecotoxicity and n-octanol/water distribution coeﬃcient data set
Publicly available aquatic ecotoxicity data from European Public
Assessment Reports (EPAR) for human medicines published by the
European Medicines Agency (EMA) or data voluntarily reported by the
pharmaceutical industry (fass.se (Vestel et al., 2015) or https://www.
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astrazeneca.com/sustainability/environmental-protection.html) were
collected in March 2016 and updated in September 2018. Since 2006,
the EU ecotoxicity assessment for drugs includes aquatic species re-
presenting three trophic levels; primary producer, plant eating in-
vertebrate and a vertebrate. The recommended chronic-eﬀects studies
are 72 h growth-inhibition test in green algae (OECD, 2011) with the
endpoints of growth rate, yield or biomass, 21 day reproduction test in
daphnia (OECD, 2012) including the endpoints growth, immobilisation
and reproductive output and ﬁsh early-life stage test, typically 32 days
(OECD, 2013) assessing the endpoints of hatching, growth and leth-
ality. Life-cycle tests in ﬁsh (approximately 300 days), which include
the endpoints of growth, lethality and reproductive output, can be re-
quested if the drug is known to aﬀect reproduction of vertebrates.
Lowest observed eﬀect concentrations (LOEC) were not accessible for
the vast majority of Daphnia and ﬁsh studies and the analyses therefore
focused on NOECs. The LOECs from the recommended chronic-eﬀects
studies can, however, at most be 3.2 times higher than the reported
NOECs, if Organisation for Economic Cooperation and Development
(OECD) guidance has been followed. The lowest NOEC for each drug
presented in any of the sources (e.g. EPAR and Fass.se) were used in the
analysis. Speciﬁc OECD test guidelines are recommended (European
Medicines Agency, 2006) and results from such tests were given pre-
cedence. Growth rate-based endpoints were given precedence when
both yield- and growth rate-based endpoints in the green algae toxicity
were reported. Yield-based endpoints were considered only if no
growth rate-based value were available. Growth-rate based on cyano-
bacteria was only considered when green algal data was absent. A
proportion of the NOECs were reported as the highest concentration
tested (25, 19 and 26% for algae, daphnia and ﬁsh respectively). This
uncertainty was considered in the analyses. For example, only drugs for
which it could be concluded that one species was more sensitive than
the other (i.e. the lowest NOEC could not be reported as the highest
concentration tested) was included in the analysis of potential links
between taxa-speciﬁc diﬀerence in toxicity and presence/absence of
drug- target orthologues. The complete list of the drugs, their associated
ecotoxicity data, with links to the sources are presented as Supple-
mentary Dataset 1.
The n-octanol/water distribution coeﬃcient (Kow or D at a speciﬁed
pH) represents the measured coeﬃcient observed in an octanol:water
partitioning study. For non-ionisable compounds, the logD does not
vary with pH but the majority of APIs are partially ionised at en-
vironmental pHs and the logKow can diﬀer substantially from logD7 for
some ionisable drugs. The pharmaceutical industry typically report
measured or predicted logD at pH 5, 7, and 9, to represent en-
vironmentally relevant conditions. In this study, reported logD7 was
given precedence and the used lipophilicity for each drug is presented
in Supplementary Dataset 2.
2.2. Drug targets and predictions of orthologues
Assignments of human drug targets and the protein-target classiﬁ-
cations (according to ChEMBL 21) were collected from Santos et al.
(2017) and DrugBank.ca (accessed February 2017). The presence and
absence of drug target orthologues was predicted in three model spe-
cies, zebraﬁsh (Danio rerio), the water ﬂea (Daphnia pulex) and the
green algae (Chlamydomonas reinhardtii) (Supplementary Dataset 1).
The adopted approach for orthology assignment was recently described
by Verbruggen et al. (2018) and ortholog predictions for all human
drug targets are available through ecodrug.org.
2.3. Calculation of a theoretical, therapeutic water concentrations for ﬁsh
A model that utilises information on mammalian pharmacology to
prioritize drugs with increased environmental hazard to ﬁsh has been
suggested (Huggett et al., 2003). This approach was used to predict the
surface water concentrations needed to reach theoretical therapeutic
plasma concentrations in ﬁsh (which we here call the “Therapeutic
Water Concentration”, TWC). In short, a partitioning coeﬃcient was
predicted using a ﬁsh-blood:water partitioning model (Eq. (1)) that is
applicable for compounds with a logKow 1–8 (Fitzsimmons et al., 2001).
= × −logK 0.73 logK 0.88blood:water ow (1)
The partitioning coeﬃcient was calculated using both the reported
log Kow/logD7–7.4 and predicted logP and log D7.4 that were collected
from chemspider.com (ACD/labs, accessed April 2017). The ﬁsh-
blood:water partitioning model was originally developed for neutral
chemicals, using log Kow as input (Fitzsimmons et al., 2001). The re-
lationship between logD and partitioning in ﬁsh, under en-
vironmentally relevant pH conditions, is less understood but the limited
number studies that have measured the blood:water partitioning of
ionisable APIs show that substitution of log Kow for logD improves
prediction of the measured plasma concentrations (Berninger et al.,
2011; Margiotta-Casaluci et al., 2014; Nallani et al., 2016). The pre-
dictions presented in Fig. 5 are, therefore, based on reported logD,
when available.
The TWCs was then calculated by relating the partitioning coeﬃ-
cient to the human Cmax level for each drug (Eq. (2)) (Huggett et al.,
2003).
=TWC C /Kmax blood:water (2)
Information regarding human therapeutic plasma concentrations
(Cmax) were retrieved from (Berninger et al., 2016; Schulz et al., 2012)
and for each drug a low and a high Cmax are presented. All TWCs,
human Cmax levels and lipophilicities are presented in Supplementary
Dataset 2.
2.4. Predicted environmental concentrations and risk quotients
European consumption data (retail, prescription and hospital data,
in kg) for 2015, were obtained from IMS Health for up to 22 European
countries. Country-speciﬁc total substance PECs were calculated as-
suming: even use across the whole population for each country (cal-
culated as mass per person per day), 100% patient use and no wastage,
no patient metabolism or sewage treatment removal, each person
generating 200 l of waste water per day and a dilution factor of 10 in
the river (as deﬁned in the for a Phase 1 PEC determination (European
Medicines Agency, 2006)). Country-speciﬁc median and 5th percentile
national annual dilution factors (Keller et al., 2014) were also used to
estimate how protective the dilution factor of 10 in the river was within
the existing guidance. Risk quotients were then calculated for each
European country with consumption data as PEC/PNEC (Supplemen-
tary Dataset 2).
3. Results
3.1. General description of the data set
Chronic environmental toxicology data from at least one of the re-
commended aquatic test species (European Medicines Agency, 2006)
were available for 19% of the approved, small molecule drugs that
target human proteins according to Drugbank (208 of 975 drugs)
(Santos et al., 2017; Wishart et al., 2008). In addition, ecotoxicological
data were also collected for 21 drugs that were not available through
Drugbank (Supplementary Dataset 1).
Twelve percent of the drugs available through Drugbank had en-
vironmental toxicology data derived from species representing three
trophic levels and together their drug targets represent 42% of all
human protein-based drug targets (Fig. 1). Most of the common phar-
macological modes of actions were represented in the dataset. For ex-
ample, more than half of the targets classiﬁed as kinases, reductases, or
G-protein coupled receptors (GPCRs) were associated with environ-
mental eﬀects data. The coverage of other target classes such as ion
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channels and “other enzyme targets” were signiﬁcantly less. Cardio-
vascular drugs inhibiting the angiotensin-converting enzyme (encoded
by ACE), antiepileptic's blocking voltage-gated T-type calcium channels
(encoded by CACNA1G, CACNA1H and CACNA1I) and muscle relaxants
inhibiting muscle-type nicotinic acetylcholine receptors (encoded by
e.g. CHRNA1 and CHRNB2) are examples of drug targets for which
there is no chronic ﬁsh toxicity data available. The thyroid hormone
receptors (encoded by THRA and THRB) or the retinoic acid receptors
(encoded by for example RXRA and RXRB) are examples of nuclear
receptors that also lack chronic ecotoxicity information from ﬁsh.
The comparison of NOECs for taxa-speciﬁc toxicology showed that
ﬁsh generally represented the most susceptible trophic level and green
algae were the least susceptible (Fig. 2a and Supplementary Fig. 3). The
PNEC for twelve drugs were lower than the EMA Phase I PEC action
trigger of 0.01 μg/l. Fish were particularly susceptible to seven drugs
targeting sex-hormone receptors or sex-steroid synthesis. Levonorges-
trel, EE2, oestradiol, etonogestrel and fulvestrant had NOECs below
0.01 μg/l, supporting that fecundity or life-cycle tests in ﬁsh should be
triggered for drugs aﬀecting sex-steroid signalling, independent of the
regulatory exposure trigger, as per the existing guidance (European
Medicines Agency, 2006; Food and Drug Administration Guidance for
Industry, 1998; Food and Drug Administration, 2016; Murray-Smith
et al., 2012). Three antineoplastic agents, regorafenib, everolimus and
ridaforolimus, also caused toxicity at very low concentrations (NOECs
of 0.007, 0.014 and 0.031 μg/l, respectively) and four additional drugs
(dalcetrapib, vortioxetine, mometasone and sorafenib in descending
order of toxicity) had PNECs below 0.1 μg/l (Fig. 2b).
3.2. Ecotoxicity and drug-target orthologues
Information on the evolutionary conservation (i.e. inference of or-
thology) could potentially help identify susceptible environmental
species (Caldwell et al., 2014; Gunnarsson et al., 2008; Verbruggen
et al., 2018). Here we used robust orthology predictions of drug targets
obtained from a recently published database (Ecodrug.com).> 90% of
all human drug targets had orthologues in zebraﬁsh (D. rerio), 64% of
the targets had orthologues in the water ﬂea (D. pulex) and 34% in the
green algae (C. reinhardtii). The number of conserved drug targets in
each species is visualized to the right in Fig. 1.
The ratio between NOECs from two species exposed to the same
drug represented a feasible approach to compare species susceptibility
across a wide range of drugs with diﬀerent physiochemical properties
and mode of toxicities. Adopting this approach, ﬁsh was shown to be
the most susceptible taxa to>70% of the drugs where conserved tar-
gets were lacking in Daphnia and green algae (Fig. 3a,c). However, if
orthologues were also present in daphnia and green algae, then their
frequency of being the most susceptible taxa were equal to ﬁsh
(Fig. 3b,d). The NOEC ratios for drugs with targets conserved only in
ﬁsh was also signiﬁcantly lower compared with the same ratio for drugs
with targets conserved in both taxa, p-value: 0.010 for NOECﬁsh/
NOECdaphnia and p-value: 0.007 NOECﬁsh/NOECalgae, Wilcoxon rank
sum test. The link between taxa-speciﬁc diﬀerences in toxicity and the
presence/absence of target orthologues was driven predominantly by
the more harmful drugs (e.g. with NOECs< 10 μg/l) and for these
drugs a linkage between the toxicity mechanism in wildlife and the
therapeutic mode of action is likely. The presence/absence of drug
target orthologues was less successful in predicting susceptible species
Fig. 1. Distribution of the environmental
toxicology data across drugs and drug-
target classes, and the evolutionary con-
servation of the drug targets. The number
of small molecule drugs (blue) and their
corresponding human protein targets
(orange) are represented by the bars on
the left-hand side of the ﬁgure. The cov-
erage of drugs available in DrugBank.ca
with a full set of aquatic environmental
eﬀects data (120) are indicated by the
darker colours inlaid within these bars.
The number of human drug targets with
orthologues in zebraﬁsh (Danio rerio), the
water ﬂea (Daphnia pulex) and the green
algae (Chlamydomonas reinhardtii) for
each protein class are shown on the right-
hand side of the ﬁgure. The shade of or-
ange corresponds to the proportion of
drug targets for which orthologues were
present. (For interpretation of the refer-
ences to colour in this ﬁgure legend, the
reader is referred to the web version of
this article.)
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for drugs with higher NOECs. Indeed, baseline toxicity, such as nar-
cosis, or toxicity mediated via oﬀ-targets is generally more likely for
drugs with high NOECs. However, the environmental risks are generally
low for such drugs as environmental exposures in surfaces waters, via
patient use and excretion, rarely exceeds concentrations of 1 μg/l.
A link between the therapeutic mode of action and the measured
toxicity is a reasonable association for many of the drugs with NOECs
below 10 μg/l. For example, the potential for drugs acting on the re-
productive axis to aﬀect reproduction in ﬁsh is well established (Kidd
et al., 2007; Lange et al., 2009; Villeneuve, 2016; Zeilinger et al., 2009)
and their drug targets (e.g. sex-steroid receptors) were not conserved in
Daphnia and green algae. Accordingly, ﬁsh were at least 1000 times
more susceptible than Daphnia and algae to ﬁve drugs targeting the
estrogen- or the progesterone receptors (encoded by ESR1 and PGR).
Invertebrates and green algae also lacked orthologues to the gluco-
corticoid receptor, NR3C1 and the NOEC for the glucocorticoids mo-
metasone and betamethasone were 1000 and 100 times lower for ﬁsh
than Daphnia and algae. Some antineoplastic agents such as lapatinib
and axitinib also lacked conserved drug targets in Daphnia and/or green
algae and their NOECs were around 100-fold lower in ﬁsh.
If the drug targets were conserved in green algae and/or Daphnia
these species were occasionally substantially more susceptible to tox-
icological eﬀects than ﬁsh (Fig. 3b and d). For example, the anti-
neoplastic agents ﬂuorouracil and vorinostat, were at least 100 times
more toxic to Daphnia and/or green algae compared to ﬁsh. Daphnia
were also particularly susceptible to exposure to the im-
munosuppressants, everolimus and ridaforolimus (150 and 35 times
more sensitive compared to ﬁsh). Their common drug target, MTOR,
acts as a central regulator of protein synthesis, cell proliferation and cell
survival in mammals and in drosophila the orthologue (dTOR) is re-
quired for normal growth during larval development (Zhang et al.,
2000). Thus, it is likely that chronic inhibition of MTOR in Daphnia
could cause growth eﬀects and/or lethality. The acute to chronic ratio
of everolimus (data are lacking for ridaforolimus) was>8000 for both
ﬁsh and Daphnia, further suggesting a speciﬁc mode of toxicity in both
taxa.
The presence/absence of drug-target orthologues was predictive of
susceptible species for all but two of the drugs with NOECs below
10 μg/l (propranolol and duloxetine Fig. 3a,c). In the case of propra-
nolol the data presented on the manufacturers website suggests that
eﬀects on growth and development of a non-standard marine echino-
derm occur at the lowest exposure concentrations (Ribeiroet al., 2015)
but invertebrates such as the echinoderm (Strongylocentrotus purpuratus)
are not predicted to have orthologs to the targets (ADRB1, ADRB2 and
ADRB3) (Bittner et al., 2018). This result may indicate a speciﬁc mode
of toxicity mediated via oﬀ-targets. It should, however, be appreciated
that tunicates such as Ciona intestinalis are predicted to have an ortholog
to the three targets and the ortholog predictions for the deuterostome
invertebrate are uncertain. It is worth emphasising also that although
the beta-blocker propranolol is one of the most studied pharmaceuticals
in the environmental literature, there are conﬂicting results regarding
the eﬀect levels in both invertebrates and ﬁsh even across relatively
similar studies (e.g. Giltrow et al. 2009; Huggett et al. 2002; Parrott and
Balakrishnan, 2017) highlighting the added uncertainty when trying to
align data from non-standard studies reported in the literature. Trans-
parent and improved reporting of non-standard as well as standard
regulatory data is urgently needed to facilitate the assessment of the
reproducibility, relevance and quality of the data from these studies, for
example according to the CRED guidance (Kase et al., 2016).
Green algae were slightly more sensitive than ﬁsh to the serotonin-
norepinephrine reuptake inhibitor, duloxetine, despite the fact that
algae lacked conserved drug targets (Fig. 3b). Duloxetine is a weak base
with a pKa around 9 and it has been shown that weak bases, which are
fully protonated, and thus cationic at a pH around 7, can exhibit
comparably high toxicity in green algae (Neuwoehner and Escher,
2011). Environmental toxicology studies with ﬁsh are typically per-
formed at a pH around 7.5 and the pH is stable throughout the ex-
periment, whereas the pH in green-algal tests typically increases
throughout the exposure due to CO2-ﬁxation. The increase in pH (up to
1.5 pH units are deemed acceptable (European Medicines Agency,
2006)) can lead to an increase of the neutral fraction of the weak bases
which can result in ion-trapping in the algal cells (Brooks et al., 2003;
Fig. 2. Distribution of No Observed Eﬀect Concentrations (NOECs) from tests with ﬁsh (grey), Daphnia (yellow) and algae (green). a| The distributions include all
available NOECs (in total for 208 drugs) and data from tests where the highest concentration did not induce any observable eﬀect (148, 160 and 204 NOECs from
ﬁsh, Daphnia and algae tests, respectively). The NOECs derived from fecundity tests in ﬁsh with drugs expected a priori to aﬀect vertebrate reproduction are marked
in black (15 drugs). Overall, green algae represented the least sensitive trophic level with signiﬁcantly higher NOECs compared to ﬁsh and Daphnia (p-values:
3.2× 10−8 and 2.8× 10−4, respectively, Wilcoxon rank sum test). Fish represented the most sensitive taxa with signiﬁcantly lower NOECs than Daphnia (p-value:
0.033). This pattern was clearer when the NOECs reported as the highest concentration tested were removed from the analysis (Supplementary Fig. 3) b| Distribution
of the Predicted No Eﬀect Concentrations (PNECs) for 127 drugs with environmental eﬀects data from ﬁsh, Daphnia and algae, excluding drugs targeting sex-steroid
receptors or sex-steroid synthesis. The Predicted Environmental Concentration (PEC) that triggers aquatic toxicity testing in the European Union (EU) and the United
States of America (USA) are indicated in the graph. The blue curve describes a ﬁtted log normal distribution (maximum likelihood estimation). (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Neuwoehner and Escher, 2011).
3.3. Environmental toxicology and drug lipophilicity
Lipophilicity is usually measured as the octanol-water partitioning
coeﬃcient and is used to rationalise the ability of drugs to cross bio-
logical membranes both in drug discovery (Lipinski et al., 1997) and in
environmental toxicology (Veith et al., 1983). The lipophilicity of in-
dustrial chemicals is generally well correlated with the environmental
toxicity for aquatic animals (Veith et al., 1983) but this relationship is
much weaker for pharmaceuticals (Vestel et al., 2015). Industrial che-
micals are to a large extent neutral, non-polar compounds while many
drugs are ionisable and the relationship between logD to partitioning,
bioaccumulation, and toxicity in aquatic species, under en-
vironmentally relevant pH conditions, is less well understood. In ad-
dition, if the drug exerts a speciﬁc mode of toxicity, for example
mediated via evolutionary conserved drug targets, a weaker correlation
would be expected compared with that driven by a general promiscuity
of the drug (e.g. narcosis). Overall, the compiled dataset reaﬃrms that
lipophilicity is an important factor aﬀecting the uptake and thus the
environmental hazard for pharmaceuticals. All the drugs with NOECs
below 1 μg/l (i.e. PNECs< 0.1 μg/l) had reported logKow or logD7–7.4
above 3 (Fig. 4). The PNECs of drugs with a lipophilicity above 3 were
signiﬁcantly lower compared to the PNECs of the other drugs (p-value:
4.9× 10−6 including all drugs and p-value: 1.6× 10−4 when PNECs
from fecundity tests in ﬁsh were excluded, Supplementary Fig. 4).
3.4. Prioritisation of legacy drugs
Fish generally represented the most susceptible trophic level and
95% of all legacy drugs had drug target orthologues in zebraﬁsh.
Results from ﬁsh early life stage tests were lacking for> 80% of drugs
targeting human proteins and methods to support their prioritisation
are needed. A model based on lipophilicity and therapeutic potency has
been suggested for prioritisation of drugs with increased environmental
hazard in ﬁsh (Brooks, 2014; Caldwell et al., 2014; Fick et al., 2010;
Huggett et al., 2003). The model assumes that ﬁsh plasma concentra-
tions can be predicted by the lipophilicity of the drug, that targets are
conserved and a speciﬁc interaction between the drug and its target(s)
in ﬁsh will result in a comparable target mediated response at a plasma
concentration similar to that necessary to elicit a therapeutic eﬀect in
humans. Concentrations above those levels will increase the probability
of oﬀ-target eﬀects and if high enough induce narcosis. Conversely, it is
assumed that toxicity in ﬁsh is unlikely to occur if water concentrations
are not high enough to produce pharmacologically active levels of drug
in the blood. The model is commonly used within academia to assess
relative environmental potency of drugs and for estimations of en-
vironmental risks when measured environmental concentrations are
Fig. 3. Analysis of potential links between taxa-speciﬁc diﬀerence in toxicity and presence/absence of drug- target orthologues. The fold-change in susceptibility
between the two compared taxa is presented on the y-axis and the silhouettes indicate which of the taxa that is the most susceptible. The lowest No Observed Eﬀect
Concentration (NOEC) of the two taxa is presented on the x-axis. The NOECs from fecundity tests in ﬁsh with drugs expected a priori to aﬀect vertebrate reproduction
are marked in black. Comparison between toxicity in ﬁsh and daphnia, a| 36 drugs with drug-target orthologues only in ﬁsh and b| 72 drugs with orthologues in both
taxa. Comparison between toxicity in ﬁsh and green algae, c| 74 drugs with drug-target orthologues only in ﬁsh and d| 30 drugs with drug targets in both taxa. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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available but pharmacologically related or chronic toxicity data for ﬁsh
(e.g. life cycle test or early-life stage test) are lacking (Brooks, 2014; Du
et al., 2014; Kristofco and Brooks, 2017).
Attempts to evaluate how well the model predicts the relative en-
vironmental toxicity of drugs as measured by eﬀects on growth, leth-
ality or fecundity have been hampered by the limited number of drugs
with available ﬁsh toxicology data (Roos et al., 2012). Here, the cor-
relations between the ﬁsh NOECs in this dataset and the modelled
‘therapeutic water concentration’ (TWC) showed some promise for ﬁrst
tier prioritisation (Pearson correlation coeﬃcient ranging from 0.51 to
0.61, Supplementary Table 5). However, the approach substantially
underestimated the toxicity for the synthetic progestin levonorgestrel
and the protein-kinase inhibitor regorafenib (> 100-fold) and to a
lesser extent for about two dozen other drugs (Fig. 5 and Supplemen-
tary Dataset 2). On the other hand, for the majority of drugs (60%), the
model over-estimated environmental potency by>10-fold. Thus, the
model needs further development from its current form to enable it to
be applicable for ﬁrst-tier prioritisation of drugs in a regulatory fra-
mework. A better understanding of the accuracy of the partitioning
model(s) is needed as well as the potential links between the ther-
apeutic potency and mechanism of actions in humans and the me-
chanism of toxicity in ﬁsh. Here we hypothesise that in ﬁsh therapeutic
modes of actions that consistently have NOECs that approach, or are
lower than, the modelled TWC, could suggest a linkage between the
eﬀects on lethality, growth or fecundity and the therapeutic mode of
action of the drug. We suggest that testing of legacy drugs with these
therapeutic modes of actions should be prioritised.
Many of the drugs aﬀecting sex-steroid receptors and synthesis in
humans (e.g. levonorgestrel, etonogestrel, EE2, letrozole, and anastro-
zole) had NOECs in ﬁsh at, or below, the modelled TWCs (Fig. 5a).
However, the selective estrogen receptor modulators ospemifene and
bazedoxifene, both used for treatment of undesired post-menopausal
symptoms, were at least 100-fold less toxic to ﬁsh than predicted. This
suggests that considerations of the degree and severity of eﬀects
associated with the human Cmax, could improve the exposure outcome
predictions in ﬁsh.
The NOECs for the serotonin re-uptake inhibitors (SRIs, vortiox-
etine, ﬂuoxetine, duloxetine and dapoxetine) in ﬁsh were all close to
the modelled TWC. While the potential for an adverse outcome as a
consequence of inhibition of the 5-hydroxytryptamine (serotonin)
transporter in ﬁsh has been suggested, experimental mechanistic in-
formation is lacking (Brooks, 2014; Groh et al., 2015; McDonald, 2017).
The high level and increasing usage of antidepressants, however, war-
rants further assessments on their environmental risks that should in-
clude an assessment of the potential eﬀects of environmentally relevant
mixtures.
The toxicity of some antineoplastic agents was substantially un-
derestimated by the model. As examples of this, the toxicities of two
kinase inhibitors (regorafenib and sorafenib) were both underestimated
by> 60-fold (Fig. 5b) and may be a reﬂection of the multi-kinase poly-
pharmacology of these two anti-VEGFR drugs. Potential links between
the therapeutic mode of action and adverse eﬀects has been suggested
for antineoplastic agents (Kümmerer et al., 2016). The relationship
between the measured toxicity and the modelled eﬀect concentration,
however, varied considerably. Kinase inhibitors often exhibit poly-
pharmacology and both on-target and oﬀ-target mediated toxicity is
relatively common (Hopkins et al., 2014; Zhang et al., 2016) which
makes it challenging to identify speciﬁc targets that could be associated
with higher environmental risk. It should also be noted that Daphnia
and green algae were the most susceptible species to many of the an-
tineoplastic agents that have conserved drug targets in these species.
Testing of this drug class should therefore be prioritised for all species
having drug-target orthologues, independent of the modelled potency
in ﬁsh.
3.5. Estimation of the environmental risks
Environmental risk is a reﬂection of both environmental hazard and
Fig. 4. Distribution of deﬁnitive PNECs for 133 drugs
with environmental eﬀects data from three taxa (drugs
with the NOEC reported from a limit test for the most
sensitive taxa, were removed from this analysis). Red
indicates NOECs for drugs with reported lipophilicity
above 3 and darker spots indicate NOECs based on ﬁsh
fecundity. (For interpretation of the references to colour
in this ﬁgure legend, the reader is referred to the web
version of this article.)
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exposure. In general, the level of exposure depends on the usage and the
environmental fate of the drug. The environmental risk assessments for
a new marketing authorisation estimate the PEC on a product-by-pro-
duct basis rather than a substance-by-substance basis (European
Medicines Agency, 2006). In the cases where a substance is used to treat
multiple clinical diseases, there is the potential to under-estimate the
environmental risks for substances used to treat diseases with a high
prevalence since diﬀerent formulations and applications are treated
separately and may not address a total PEC. Here, we calculated PECs
using a substance-based approach, using EU wide consumption data,
and the worst-case exposure assumptions (European Medicines Agency,
2006).
Seven drugs (levonorgestrel, EE2, estradiol, abiraterone, propra-
nolol, fulvestrant and ﬂuoxetine) had PECs that exceeded their corre-
sponding PNEC, in at least one European country (Fig. 6). There were,
however, substantial diﬀerences between countries (often two orders of
magnitude), which reﬂects diﬀerent preferences for drugs to treat
speciﬁc diseases, diﬀerences in disease epidemiology (as prevalence can
vary between countries), and/or diﬀerences in product approval at the
national level. Four drugs aﬀecting sex-steroid signalling had median
risk quotients of above 10 suggesting the potential for high environ-
mental risks in many of the European countries. As a consequence of the
placement of EE2 and oestradiol on the European Water Framework
Directive Watch List (Commission of the European Union, 2015) the
current EU-wide monitoring of these sex steroids will support exposure
reﬁnements to better validate their PECs.
The PECs used to calculate environmental risk within our analysis
assumed the EU-wide regulatory default dilution factor of 10 (i.e. do-
mestic sewage eﬄuents are diluted ten-fold to estimate the surface
water concentration of the drug), which is deemed to be conservative
given that median estimated dilution is 18 and higher in the assessed
European countries (Keller et al., 2014). However, 5% of catchments in
Europe, including in Belgium (lowest annual median ﬂows in Europe),
Hungary, Netherlands, Romania, Spain and UK can have lower dilu-
tions, especially during low ﬂow conditions, and this generic dilution
factor could underestimate environmental drug concentrations in some
receiving environments (Link et al., 2017). The number of drugs with a
risk quotient above one in any of the European countries was reduced to
ﬁve when country speciﬁc dilution factors (median) were used (Sup-
plementary Fig. 7). However, if the 5th percentile dilution factors were
used 15 drugs had a risk quotient above one (Supplementary 8). For
example, the risk quotient were above 1 also for ibuprofen (Spain),
sorafenib (Spain and Romania), celecoxib (Spain), naproxen (UK),
dronedarone (Spain), carbamazepine (Hungary, UK and Romania),
metformin (UK, Romania and Spain) and duloxetine (Belgium and
Spain).
4. Discussion
Here we present an analysis of the publicly-available and reg-
ulatory-compliant ecotoxicity data for human drugs to provide a much
needed information database for the development of more intelligent
approaches for environmental drug testing. We show that presence/
absence of drug-target orthologues is predictive of susceptible species
based on standardized model organisms and endpoints. The risk as-
sessment conﬁrmed that drugs targeting the endocrine system re-
presented the highest potency and greatest risk. The assessment also
showed that only a small number of the drugs were predicted to pose
signiﬁcant environmental risks (PEC/PNEC > 1) based on European
sales statistics, worst-case exposure assumptions and the endpoints in-
cluded in regulatory testing (eﬀects on, growth, mortality and/or re-
production). Importantly, the compiled data set also suggest that
chronic ecotoxicity data is lacking for 88% of the drugs targeting
human proteins. We suggest the results presented can guide improve-
ments to current testing procedures, and provides a valuable approach
for prioritising legacy drugs (i.e. those registered before 2006) for
further ecotoxicity testing.
The presence/absence of drug-target orthologues is a key factor that
predicts species susceptibility for drug exposure at low concentrations.
The substantial diﬀerence in toxicity across species highlights that the
European transition to chronic ecotoxicological testing in 2006
(European Medicines Agency, 2006) was justiﬁed. Most medicinal
products approved before 2006 lack chronic testing in ﬁsh and their
associated PNEC may therefore not be protective for ﬁsh if it is based on
short-term acute tests or on species that lack drug-target orthologues.
On the other hand, our results question the current need to always
include tests with Daphnia and green algae in the environmental risk
assessment of new or legacy drugs where the drug target is conserved
only in ﬁsh. This highlights the potential for development of appro-
priate science-based assessment factors to extrapolate ecotoxicity data
from species with drug-target orthologues to protect species lacking
targets.
The European exposure (PEC) trigger (0.01 μg/l) for toxicity testing
is based on historical acute environmental toxicology data only
(European Medicines Agency, 2006). Our analyses suggest that this
trigger is conservative for hydrophilic drugs. All the drugs with NOECs
below 1 μg/l (i.e. PNECs< 0.1 μg/l) had reported logKow or logD7–7.4
above 3. However, the hydrophilic drugs propranolol (logD: 1.6) and
ﬂuorouracil (logD: −0.89) had relatively low NOECs (2 and 2.8 μg/l,
respectively) but relatively high potencies. A pragmatic way forward to
develop a ﬁrst screen prioritisation for legacy APIs would be to base it
on consumption data. If the consumption-based PEC in any EU country
is> 100 ng/l then it should be prioritised, whereas if the consumption-
based PEC for all EU countries is< 10 ng/l and data already exist for
that MoA then is should be considered as low priority. If the PEC for the
EU country with highest use is 10–100 ng/l and the API has a log
Kow>3 then this would be considered as a high priority and for APIs
with a log Kow<3 for the same PECs of 10–100 ng/l, a medium
priority. Such an approach however should be subject to re-iterative
review and potentially modiﬁcations as more data becomes available.
The conducted risk assessment, based on the regulatory compliant
assessment test endpoints, European consumption statistics, and
country speciﬁc annual dilution factors (5th percentile), predicted
that> 80% of the drugs in the dataset have a risk quotient below 1 for
all of the individual 22 European countries analysed. The predictions
assumed 100% patient use and no wastage, no patient metabolism or
sewage treatment removal. However there are some uncertainties that
could lead to higher environmental concentrations or ‘hot spots’, for
example, higher spatial concentrations due to population demo-
graphics, seasonal diﬀerences in dilution factor, or poorly managed
wastewaters from manufacturing (Larsson, 2014; Weber et al., 2015).
Nevertheless, most of the measured concentrations in European surface
waters were substantially lower than the presented PECs. It is important
to note also that the amount of data for water measurements varies
across the diﬀerent drugs. As an example, concentrations of levo-
norgestrel have been analysed in only 14 samples from European
Fig. 5. Comparison of measured environmental eﬀects in ﬁsh and a theoretical “therapeutic water concentration”. A ratio between the No Observed Eﬀect
Concentration (NOEC) and the modelled “therapeutic water concentration” (TWC) below 1 suggest that the model underestimated the environmental eﬀect whereas
a ratio above 1 suggest an overestimation. Drug targets are presented on the left-hand side in the ﬁgure and the associated drugs to the right. The TWC was calculated
using both a high and a low human therapeutic plasma concentration (the lower Cmax is indicated by the bigger symbol). A ﬁxed partitioning coeﬃcient of 0.7 was
applied to drugs with reported logD<1. a| Drug targets associated with ﬁsh NOECs from at least three drugs. The targets PGR, CYP191A, ESR1 and ESR2 were
included despite only being associated with ﬁsh NOECs from two drugs. b| Drug-target kinases associated with ﬁsh NOECs from at least three antineoplastic agents.
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Fig. 6. Drugs with substance risk quotients with a margin of safety < 100-fold in all the assessed countries. The environmental risk is calculated by dividing the
Predicted Environmental Concentration (PEC) with the Predicted No Eﬀect Concentration (PNEC). For each drug the Anatomical Therapeutic Chemical (ATC)
classiﬁcation code and the No Observed Eﬀect Concentrations (NOEC) for the most susceptible taxa are presented in the columns. Bold ATC codes indicate that the
drug has triggered fecundity tests with ﬁsh. The colours of the boxes show the environmental risk, based on the country with the highest ratio, according to the fass.se
scheme: high risk (PEC/PNEC>10; red), moderate risk (PEC/PNEC>1–10; orange), low risk (PEC/PNEC>0.1–1; yellow) and insigniﬁcant risk (PEC/PNEC<0.1;
green). The median and the interquartile range (i.e. 50% of data in this range) are shown in the box and the whiskers indicate the min/max data point 1.5 times in
distance from the ﬁrst and third quartile. The complete list of risk quotients for all drugs assessed is available as S6 Figure. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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surface water whereas EE2, ﬂuoxetine and propranolol have each been
analysed in at least 500 samples. The inclusion of additional drugs (e.g.
levonorgestrel) in the EU-wide monitoring (Commission of the
European Union Decision, 2015) warrants consideration to better es-
tablish their surface water concentrations.
The environmental risks of human medicinal products are deﬁned in
Article 8(3) of Directive 2001/83/EC, as “any risk of undesirable eﬀects
on the environment”. The ecological protection goal, however, is at the
population and ecosystem services level. Potential molecular, cell or
tissue level eﬀects or eﬀects on behaviour are therefore not considered.
There is a growing concern regarding behavioural alterations that may
aﬀect wildlife populations (Brodin et al., 2013; Hellström et al., 2016;
Klaminder et al., 2014; Rand-Weaver et al., 2013). A better under-
standing of behavioural traits and eﬀects is needed to determine the
ecological relevance of these reported eﬀects (Brodin et al., 2014;
Brooks, 2014). There is also an ongoing debate regarding the potential
use of non-standard endpoints, such as histological alterations that in-
dicate tissue damage, in environmental risk assessment of human drugs.
For example, the environmental risk assessment for diclofenac based on
standard OECD tests provides a NOEC of 320 μg/l, which is based on
eﬀects on survival of larvae and juvenile zebraﬁsh (Memmert et al.,
2013). A slightly higher NOEC (369 μg/l) for histological alterations in
gills of rainbow trout is reported in the same article. Several other
studies have shown histological and molecular eﬀects, in the kidney
and other organs, in ﬁsh exposed to diclofenac at substantially lower
concentrations, ranging from 1 to 25 μg/l (Bickley et al., 2017; Mehinto
et al., 2010; Näslund et al., 2017; Schwaiger et al., 2004; Triebskorn
et al., 2004). As with behavioural eﬀects, there is a need to extrapolate
molecular, cellular, tissue, organ and individual level eﬀects to the
ecosystem level in order to determine the signiﬁcance of these varia-
tions in wild populations. There is also a need to develop approaches to
assess the risks associated with long-term exposure to mixtures of
pharmaceuticals and other environmental stressors (Boxall et al.,
2012).
Furthermore, environmental assessments are typically conducted
only once, at the point of authorisation and unlike the ongoing phar-
macovigilance requirements to provide patient safety updates, en-
vironmental assessments are rarely reﬁned in light of emerging scien-
tiﬁc data; consequently, there is a need to update environmental
assessments if robust and reliable data are published that has a material
impact on the NOEC for a given drug (Holm et al., 2013). Making en-
vironmental data for human pharmaceuticals more widely available
through the development of a central and searchable substance data-
base would greatly enhance the environmental assessments of phar-
maceuticals.
The growing regulatory and scientiﬁc concerns regarding pharma-
ceuticals in the environment have reached the point where some sta-
keholders are advocating the inclusion of environmental hazard and
risk within the patient-beneﬁt evaluation that underpins the marketing
authorisation of a drug (Ågerstrand et al., 2014; BIO Intelligence
Service, 2013). Currently the environmental risk assessment is con-
ducted in parallel to Phase III clinical trials, i.e. after signiﬁcant in-
vestment in drug discovery and development. The dataset we have
collated in this study; however, indicates that most drugs pose low risk
based on the regulatory test endpoints measured and the usage levels in
Europe. Irrespective of the outcome of this ongoing regulatory debate it
is critical that predictive in silico, in vitro and in vivo tools and models
are developed and integrated earlier within drug development to
identify environmental concerns much sooner than operates within the
current industry model. These tools will be useful in helping to identify
drugs of potential environmental concern and ensure that the right
species are chosen for a tailored environmental assessment. The avail-
ability of these tools and models will also assist with the prioritisation
of the> 800 legacy drugs that lack any environmental data for deﬁ-
nitive regulatory assessments. Identifying drugs, whether new sub-
stances or legacy drugs, of potential environmental concern and
deriving appropriate PNECs will help to focus monitoring eﬀorts, en-
sure establishing safe discharge levels from manufacturing and muni-
cipal sewage treatment plants, and ultimately help direct mitigation
eﬀorts to minimise the environmental eﬀect of drugs. The dataset
presented in this study provides a fundamental underpinning for more
intelligent approaches for drug testing for environmental protection,
directing testing eﬀorts on drugs that pose the greatest environmental
risks whether new substances or legacy drugs.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.envint.2019.04.075.
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